TABLE 2.
Basic characteristics of nine patients with NGS testing.
| Patient No. | Gender | Age | Smoking history | ECOG | Stage | EGFR mutation | PFS of Osimertinib (months) | Osimertinib PD model |
| 1 | M | 61 | No | 1 | IVa | L858R | 8 | Extrathoracic |
| 2 | M | 62 | No | 2 | IVb | 19-del | 8 | Extrathoracic |
| 3 | F | 55 | No | 1 | IVa | L858R | 12 | Intrathoracic |
| 4 | F | 44 | No | 1 | IVb | G719A | 6 | Intrathoracic |
| 5 | F | 54 | No | 1 | IVa | L858R | 2 | Intrathoracic |
| 6 | F | 66 | No | 2 | IVa | 19-del | 11 | Intrathoracic |
| 7 | M | 35 | No | 1 | IVb | L858R | 6 | Intrathoracic |
| 8 | M | 62 | No | 1 | IVb | L858R | 12 | Extrathoracic |
| 9 | F | 53 | No | 1 | IVb | L858R | 8 | Intrathoracic |